Biogen Inc.
- Jurisdiction
United States - LEI
W8J5WZB5IY3K0NDQT671 - ISIN
US09062X1037 (BIIB )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€212.49 63.8% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Read full profile
Fundamentals
- Net revenue
€8.53B - Gross margin
75.4% - EBIT
€2.07B - EBIT margin
24.2% - Net income
€1.31B - Net margin
15.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Robert Bresnahan | June 9, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | May 8, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | March 27, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| Samantha McLemore |
|
|
|
Buy |